5.81
0.00%
0.00
Schlusskurs vom Vortag:
$5.81
Offen:
$5.78
24-Stunden-Volumen:
31,652
Relative Volume:
0.92
Marktkapitalisierung:
$327.42M
Einnahmen:
$154.57M
Nettoeinkommen (Verlust:
$15.07M
KGV:
72.62
EPS:
0.08
Netto-Cashflow:
$10.92M
1W Leistung:
-0.17%
1M Leistung:
+10.04%
6M Leistung:
+9.62%
1J Leistung:
+21.80%
Kamada Ltd Stock (KMDA) Company Profile
Vergleichen Sie KMDA mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
KMDA
Kamada Ltd
|
5.81 | 327.42M | 154.57M | 15.07M | 10.92M | 0.08 |
ZTS
Zoetis Inc
|
176.74 | 80.59B | 9.15B | 2.43B | 2.31B | 4.92 |
HLN
Haleon Plc Adr
|
9.72 | 44.17B | 14.26B | 1.55B | 0 | 0.3327 |
TAK
Takeda Pharmaceutical Co Adr
|
13.57 | 42.61B | 30.27B | 1.93B | 3.45B | 0.444 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.57 | 18.77B | 16.77B | -959.00M | 1.37B | -2.00 |
VTRS
Viatris Inc
|
13.22 | 15.73B | 15.05B | -883.30M | 1.89B | 1.53 |
Kamada Ltd Stock (KMDA) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2024-07-03 | Eingeleitet | Stifel | Buy |
2018-02-02 | Eingeleitet | Chardan Capital Markets | Buy |
Kamada Ltd Aktie (KMDA) Neueste Nachrichten
Solid Earnings Reflect Kamada's (TLV:KMDA) Strength As A Business - Simply Wall St
Alpha 1 Antitrypsin Deficiency Treatment Market Analysis By Top - openPR
HC Wainwright Issues Pessimistic Outlook for Kamada Earnings - MarketBeat
What is HC Wainwright’s Forecast for Kamada FY2024 Earnings? - Defense World
Alpha-1 Antitrypsin Deficiency Therapy Market 2024-2031 - openPR
HC Wainwright Forecasts Kamada's Q4 Earnings (NASDAQ:KMDA) - MarketBeat
Earnings call: Kamada Ltd. reports growth and raises EBITDA outlook - Investing.com India
Phoenix Financial Ltd. Increases Stake in Kamada Ltd. - GuruFocus.com
Kamada Ltd. (NASDAQ:KMDA) Q3 2024 Earnings Call Transcript - Insider Monkey
Kamada Ltd (KMDA) Q3 2024 Earnings Call Highlights: Strong Reven - GuruFocus.com
Kamada Ltd (KMDA) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Increased EBITDA ... - Yahoo Finance
Type 1 Alpha-1 Antitrypsin Deficiency Treatment Market to Grow - openPR
Alpha-1 Antitrypsin Deficiency Market Expected to Experience Major Growth by 2034, According to DelveInsight | Kamada Pharma, Mereo BioPharma/AstraZeneca, Grifols Therapeutics LLC, Takeda, Vertex - Barchart
Earnings call: Kamada Ltd. reports growth and raises EBITDA outlook By Investing.com - Investing.com Australia
Kamada: Q3 Earnings Snapshot - Barchart
Kamada reports Q3 EPS 7c, consensus 7c - TipRanks
Kamada’s Strong Growth and Strategic Expansion in 2024 - TipRanks
KMDAKamada Ltd Latest Stock News & Market Updates - StockTitan
Kamada Reports Continued Profitable Growth with Strong Third Quarter and Nine Month 2024 Financial Results; Raises Full-Year Profitability Guidance - The Manila Times
Kamada Reports Continued Profitable Growth with Strong - GlobeNewswire
Kamada Q3 Revenue Surges 10% to $41.7M, Boosts EBITDA Guidance Amid Strong Growth | KMDA Stock News - StockTitan
Cystic Fibrosis Market Size to be Worth USD 55.4 Billion by 2032, with a Projected CAGR of 21.6% - WICZ
Report shares who was actually responsible for bringing Daichi Kamada to Crystal Palace - We Are Palace
Alpha 1 Lung Disease Market Growth Set to Surge Significantly by 2031 As Revealed In New Report - WhaTech
What fixtures Daichi Kamada will miss for Crystal Palace after red card in 2-0 Fulham defeat - We Are Palace
Kamada (KMDA) Scheduled to Post Earnings on Wednesday - MarketBeat
Alvotech Attending Citi's Global Healthcare Conference on December 4, 2024, and Evercore's HealthCONx Conference on December 5, 2024 - The Manila Times
Kamada Ltd. sets Q3 earnings call for November 13 - Investing.com India
Kamada to Release Q3 Financial Results Amid Global Expansion - TipRanks
Kamada to Announce Third Quarter and Nine-Months Ended September 30, 2024 Financial Results and Host Conference Call on November 13, 2024 - The Manila Times
Kamada to Announce Third Quarter and Nine-Months Ended - GlobeNewswire
Kamada (KMDA) Sets Q3 2024 Earnings Call for November 13What to Expect | KMDA Stock News - StockTitan
Stratasys unveils new IoT platform for 3D printing operations By Investing.com - Investing.com South Africa
Kamada to Present at the Stifel 2024 Healthcare Conference - GlobeNewswire
Kamada to Present at Stifel Healthcare Conference - TipRanks
Earnings growth outpaced the 24% return delivered to Kamada (TLV:KMDA) shareholders over the last year - Simply Wall St
Blood Plasma Market to Grow by USD 15.9 Billion (2024-2028) as Innovative Solutions Address Global Blood Shortage; Report Highlights AI's Impact on Market TrendsTechnavio - The Malaysian Reserve
Global Healthcare & Medical Tourism News - Medical Tourism Magazine
Global Plasma Protein Therapeutics Market to Touch ~USD 40 Billion Mark by 2030 | DelveInsight - GlobeNewswire
What Jean-Philippe Mateta did after Daichi Kamada scored in Aston Villa 1-2 Crystal Palace, it was telling - We Are Palace
Kamada strike secures Quarter-Final spot - Holmesdale Online
Aston Villa 1-2 Crystal Palace: Daichi Kamada fires Eagles into last eight of Carabao Cupbut visitors lose - Daily Mail
Alvotech to Report Financial Results for the First Nine Months of 2024 on November 13, 2024, and Host Conference Call on November 14, 2024, at 8:00 am ET - The Manila Times
Alvotech to Report Financial Results for the First Nine - GlobeNewswire
Alvotech Meeting Investors and Presenting at the Jefferies 2024 London Healthcare Conference on November 19-20, 2024 - The Manila Times
Alvotech Meeting Investors and Presenting at the Jefferies - GlobeNewswire
Kamada (NASDAQ:KMDA) Shares Cross Below Two Hundred Day Moving AverageHere's What Happened - MarketBeat
Kamada Ltd. Announces 2024 Annual General Meeting - TipRanks
Alpha 1 Lung Disease Market Projected to Reach $19.93 Billion by 2031 with 19.33% CAGR - WhaTech
Kamada Ltd. (NASDAQ:KMDA) Short Interest Update - MarketBeat
Finanzdaten der Kamada Ltd-Aktie (KMDA)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):